Article
The FDA has approved Refocus Group's request to begin phase II clinical trials of its scleral implants and scleral spacing procedure for the surgical treatment of presbyopia.
Melt Pharmaceuticals reports positive Phase 3 topline efficacy results for MELT-300
(EyePod) From idea to impact: Navigating ophthalmic innovation
Study explores the true costs of treating pediatric cataracts
EyePod: Integrating cutting-edge pipeline devices for enhanced cataract surgery
Study: Aromatherapy decreased postoperative patient anxiety and pain associated with oculoplastic surgery
Raising cataract surgery procedure to an art and an experience